In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo. Friedman JH. Ann Intern Med 2024 Sep 3. doi: 10.7326/ANNALS-24-01662.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Friedman JH. In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo. Ann Intern Med 2024 Sep 3. doi: 10.7326/ANNALS-24-01662.
PMID: 39222514